glp 1 agonists and sglt2 inhibitors combination Cardiorenal Protection: Potential of GLP-1 Receptor in the Treatment of Type 2 Diabetes | Diabetes Therapy Updated evidence on cardiovascular and
Description
and S.Q
Hattori Y, Jojima T, Tomizawa A, et al
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
Mixed treatment comparisons against GLP-1 RAs showed no significant differences for SGLT2is/metformin (WMD: 0.51
in the pancreas, bone tissue, and vasculature
Administration of glucose or fat directly into the duodenum of such rodents rapidly stimulates L-cell GLP-1 secretion, with a magnitude comparable to that occurring when nutrients are directly placed into the ileum [289,320]
